What the business is, and whether it's a good one at a fair price.
Makes branded and unbranded generic medicines in India, the United States, Africa and Asia across cardiology, ophthalmology, dermatology and pain therapy. In FY26, India branded generics and US generics were the two largest revenue contributors, while Africa branded generics grew strongly and Asia branded generics dipped modestly due to Middle East supply-chain disruption. The India business sells through a field force and outpaced industry growth in Q1 FY27, with gains spread across cardio, ophthalmology, dermatology and pain. In the US, the company files abbreviated new drug applications (ANDAs) for the generics market, and its Paithan manufacturing facility received a Voluntary Action Indicated classification from the US FDA in 2026, confirming acceptable compliance. The company is expanding manufacturing capacity at Pithampur to support future launches. In FY26, other operating expenses and employee costs were the largest cost lines at 29% and 23.7% of revenue respectively, with materials at 16.8%, reflecting the field-force-intensive branded-generics model.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AJANTA PHARMA LIMITED's filed financials and exchange disclosures
AJANTA PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AJANTPHARM.
Yes. Over the trailing twelve months AJANTA PHARMA LIMITED reported a net profit of ₹1,135 Cr on revenue of ₹5,776 Cr.
Yes. The dividend yield is 0.78% at the current price. It paid out 33% of its profit as dividend in FY26.
No. Debt stands at 0.05× equity, and it carries net debt of ₹109 Cr. That is lower than 59% of its 171 Pharmaceuticals peers.
On trailing P/E, AJANTA PHARMA LIMITED ranks 111 of 169 in Pharmaceuticals — cheaper than 35% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AJANTA PHARMA LIMITED moves 1.00% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AJANTA PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
